Barriers and enablers to deprescribing in people with a life-limiting disease: A systematic review

Palliative Medicine

Volumn 33, Issue 1, 2019, Pages 37-48

  Paque, Kristel ^a,b   Vander Stichele, Robert ^a   Elseviers, Monique ^a,c   Pardon, Koen ^b   Dilles, Tinne ^c,d   Deliens, Luc ^b,e   Christiaens, Thierry ^a  

^a GHENT UNIVERSITY   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d Thomas More University College   (Belgium)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

deprescriptions; Drug utilization; palliative care; systematic review

Indexed keywords

CAREGIVER; DEPRESCRIPTION; GENERAL PRACTITIONER; HEALTH CARE PERSONNEL; HUMAN; INTERPERSONAL COMMUNICATION; PALLIATIVE THERAPY; PHARMACIST; PREVALENCE; PRIMARY MEDICAL CARE; QUALITY CONTROL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); DECISION MAKING; DRUG UTILIZATION; PROCEDURES; TERMINAL CARE; TREATMENT WITHDRAWAL;

DECISION MAKING; DEPRESCRIPTIONS; DRUG UTILIZATION; HUMANS; PALLIATIVE CARE; TERMINAL CARE; WITHHOLDING TREATMENT;

EID: 85056787512     PISSN: 02692163     EISSN: 1477030X     Source Type: Journal    
DOI: 10.1177/0269216318801124     Document Type: Review

References (54)

1. Heppenstall CP, Broad JB, Boyd M. Medication use and potentially inappropriate medications in those with limited prognosis living in residential aged care. Australas J Ageing 2016; 35(2): E18–E24
2. Kotlinska-Lemieszek A, Paulsen O, Kaasa S. Polypharmacy in patients with advanced cancer and pain: a European cross-sectional study of 2282 patients. J Pain Symptom Manage 2014; 48(6): 1145–1159
3. McNeil MJ, Kamal AH, Kutner JS. The burden of polypharmacy in patients near the end of life. J Pain Symptom Manage 2016; 51(2): 178–183
4. Frechen S, Zoeller A, Ruberg K. Drug interactions in dying patients: a retrospective analysis of hospice inpatients in Germany. Drug Saf 2012; 35(9): 745–758
5. Gaertner J, Ruberg K, Schlesiger G. Drug interactions in palliative care: it’s more than cytochrome P450. Palliat Med 2012; 26(6): 813–825
6. Morgan NA, Rowett D, Currow DC., Analysis of drug interactions at the end of life. BMJ Support Palliat Care 2015; 5(3): 281–286
7. Barceló M, Torres O, Ruiz D. Appropriateness of medications prescribed to elderly patients with advanced heart failure and limited life expectancy who died during hospitalization. Drugs Aging 2014; 31(7): 541–546
8. Morin L, Vetrano DL, Grande G. Use of medications of questionable benefit during the last year of life of older adults with dementia. J Am Med Dir Assoc 2017; 18(6): 551e1–551e7
9. Tjia J, Briesacher BA, Peterson D. Use of medications of questionable benefit in advanced dementia. JAMA Intern Med 2014; 174(11): 1763–1771
10. LeBlanc TW, McNeil M, Kamal AH. Polypharmacy in patients with advanced cancer and the role of medication discontinuation. Lancet Oncol 2015; 16(7): E333–E341
11. Maddison AR, Fisher J, Johnston G., Preventive medication use among persons with limited life expectancy. Prog Palliat Care 2011; 19(1): 15–21
12. Todd A, Nazar H, Pearson H. Inappropriate prescribing in patients accessing specialist palliative day care services. Int J Clin Pharm 2014; 36(3): 535–543
13. Reeve E, Shakib S, Hendrix I. Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. Br J Clin Pharmacol 2014; 78(4): 738–747
14. Reeve E, Gnjidic D, Long J. A systematic review of the emerging definition of ‘deprescribing’ with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol 2015; 80(6): 1254–1268
15. Scott IA, Hilmer SN, Reeve E. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med 2015; 175(5): 827–834
16. Iyer S, Naganathan V, McLachlan AJ. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging 2008; 25(12): 1021–1031
17. Kutner JS, Blatchford PJ, Taylor DH, Jr. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med 2015; 175(5): 691–700
18. Moonen JE, Foster-Dingley JC, de Ruijter W. Effect of discontinuation of antihypertensive treatment in elderly people on cognitive functioning: the DANTE study Leiden: a randomized clinical trial. JAMA Intern Med 2015; 175(10): 1622–1630
19. Anderson K, Stowasser D, Freeman C. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open 2014; 4(12): e006544
20. Narayan SW, Nishtala PS., Discontinuation of preventive medicines in older people with limited life expectancy: a systematic review. Drugs Aging 2017; 34(10): 767–776
21. Poudel A, Yates P, Rowett D. Use of preventive medication in patients with limited life expectancy: a systematic review. J Pain Symptom Manage 2017; 53(6): 1097–1110
22. Reeve E, Bell JS, Hilmer SN., Barriers to optimising prescribing and deprescribing in older adults with dementia: a narrative review. Curr Clin Pharmacol 2015; 10(3): 168–177
23. Reeve E, To J, Hendrix I. Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging 2013; 30(10): 793–807
24. Moher D, Liberati A, Tetzlaff J. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62(10): 1006–1012
25. Cochrane handbook for systematic reviews of interventions version 5.1.0. 2011, http://training.cochrane.org/handbook
26. Shamseer L, Moher D, Clarke M. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015; 350: g7647
27. Covidence. Accelerate your systematic review, https://www.covidence.org
28. Critical Appraisal Skills Programme. CASP qualitative research checklist. 2017, http://www.casp-uk.net/casp-tools-checklists
29. Joanna Briggs Institute. Critical appraisal checklist for analytical cross sectional studies. 2017, http://joannabriggs.org/research/critical-appraisal-tools.html
30. Center for Evidence-Based Management. Critical appraisal checklist for cross-sectional study. 2014, https://www.cebma.org
31. Alves A, James D, Green S., Deprescribing of medicines in care homes – primary care pharmacists’ practices and perspectives. Int J Pharm Pract 2016; 24: 37–38
32. Bolmsjö BB, Palagyi A, Keay L. Factors influencing deprescribing for residents in advanced care facilities: insights from general practitioners in Australia and Sweden. BMC Fam Pract 2016; 17: 152
33. Hopper I, de Silva C, Skiba M. Attitudes of patients and prescribing clinicians to polypharmacy and medication withdrawal in heart failure. J Card Fail 2016; 22(9): 743–744
34. Jansen J, McKinn S, Bonner C. General practitioners’ decision making about primary prevention of cardiovascular disease in older adults: a qualitative study. PLoS ONE 2017; 12(1): e0170228
35. Leten L, Azermai M, Wauters M. A qualitative exploration of the chronic use of psychotropic drugs in nursing homes. Tijdschr Gerontol Geriatr 2017; 48: 177–186
36. Page AT, Clifford RM, Potter K. Exploring the enablers and barriers to implementing the Medication Appropriateness Tool for Comorbid Health conditions during Dementia (MATCH-D) criteria in Australia: a qualitative study. BMJ Open 2017; 7(8): e017906
37. Parsons C, McCorry N, Passmore P. Assessment of factors which influence GP decision-making regarding medication use in patients with dementia at the end of life. Int J Pharm Pract 2011; 19: 14
38. Sand AM, Harris J, Rosland JH., Living with advanced cancer and short life expectancy: patients’ experiences with managing medication. J Palliat Care 2009; 25(2): 85–91
39. Sawan M, Jeon YH, Fois RA. Exploring the link between organizational climate and the use of psychotropic medicines in nursing homes: a qualitative study. Res Social Adm Pharm 2017; 13(3): 513–523
40. Shega JW, Ellner L, Lau DT. Cholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use in older adults with end-stage dementia: a survey of hospice medical directors. J Palliat Med 2009; 12(9): 779–783
41. Tjia J, Kutner JS, Ritchie CS. Perceptions of statin discontinuation among patients with life-limiting illness. J Palliat Med 2017; 20: 1098–1103
42. Todd A, Holmes H, Pearson S. ‘I don’t think I’d be frightened if the statins went’: a phenomenological qualitative study exploring medicines use in palliative care patients, carers and healthcare professionals. BMC Palliat Care 2016; 15: 13
43. Velasco Arribas M, Vegas Serrano A, Guijarro Herraiz C. End-of-life decisions: foregoing antibiotic therapy in patients with an active infection. Rev Esp Geriatr Gerontol 2006; 41(5): 297–300
44. Sawan MJ, Jeon YH, Fois RJ. A qualitative study exploring visible components of organizational culture: what influences the use of psychotropic medicines in nursing homes? Int Psychogeriatr 2016; 28(10): 1725–1735
45. Tjia J, Velten SJ, Parsons C. Studies to reduce unnecessary medication use in frail older adults: a systematic review. Drugs Aging 2013; 30(5): 285–307
46. Kaur S, Mitchell G, Vitetta L. Interventions that can reduce inappropriate prescribing in the elderly: a systematic review. Drugs Aging 2009; 26(12): 1013–1028
47. Riordan DO, Walsh KA, Galvin R. The effect of pharmacist-led interventions in optimising prescribing in older adults in primary care: a systematic review. SAGE Open Med 2016; 4. DOI: 10.1177/2050312116652568
48. Palagyi A, Keay L, Harper J. Barricades and brickwalls: a qualitative study exploring perceptions of medication use and deprescribing in long-term care. BMC Geriatr 2016; 16: 15
49. Ailabouni NJ, Nishtala PS, Mangin D. Challenges and enablers of deprescribing: a general practitioner perspective. PLoS ONE 2016; 11(4): e0151066
50. Wallis KA, Andrews A, Henderson M., Swimming against the tide: primary care physicians’ views on deprescribing in everyday practice. Ann Fam Med 2017; 15(4): 341–346
51. Irving G, Neves AL, Dambha-Miller H. International variations in primary care physician consultation time: a systematic review of 67 countries. BMJ Open 2017; 7(10): e017902
52. Dilles T, Vander Stichele RH, Van Bortel LM. The development and test of an intervention to improve ADR screening in nursing homes. J Am Med Dir Assoc 2013; 14(5): 379e1–379e6
53. Turner JP, Edwards S, Stanners M. What factors are important for deprescribing in Australian long-term care facilities? Perspectives of residents and health professionals. BMJ Open 2016; 6(3): e009781
54. Šarić L, Prkić I, Jukić M., Futile treatment: a review. J Bioeth Inq 2017; 14(3): 329–337